OS Therapies (OSTX) Stock Price, News & Analysis

Company Overview

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Key Stats

• Today's Range: $1.56 to $1.63
• 50-Day Range: $1.46 to $2.24
• 52-Week Range: $1.15 to $2.57
• Volume: 401,244 shs
• Average Volume: 282,064 shs
• Market Capitalization: $73.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.33
• Consensus Rating: Moderate Buy

OS Therapies Stock Analysis - MarketRank™

OS Therapies scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OS Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

OS Therapies has a consensus price target of $13.33, representing about 723.0% upside from its current price of $1.62.

Amount of Analyst Coverage

OS Therapies has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OS Therapies are expected to grow in the coming year, from ($0.94) to $0.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OS Therapies is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OS Therapies is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.74% of the float of OS Therapies has been sold short.

Short Interest Ratio / Days to Cover

OS Therapies has a short interest ratio ("days to cover") of 8.54.

Change versus previous month

Short interest in OS Therapies has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OS Therapies does not currently pay a dividend.

Dividend Growth

OS Therapies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.21

News Sentiment

OS Therapies has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for OS Therapies this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for OSTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OS Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of OS Therapies is held by insiders.

Percentage Held by Institutions

OS Therapies has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:OSTX
• Previous Symbol: NYSE:OSTX
• CIK: 1795091
• Web: ostherapies.com
• Phone: (410) 297-7793
• Fax: N/A
• Employees: N/A
• Year Founded: 2018

Price Target and Rating

• Average Price Target for OS Therapies: $13.33
• High Price Target: $20.00
• Low Price Target: $7.00
• Potential Upside/Downside: +723.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -422.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.05
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.17) per share
• Price / Book: -9.53

Miscellaneous

• Outstanding Shares: 45,540,000
• Free Float: 41,166,000
• Market Cap: $73.77 million
• Optionable: N/A
• Beta: -0.73